secwatch.observer — SEC 8-K summary
======================================

Issuer:     bluebird bio, Inc. (—)
CIK:        0001293971
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001193125-25-132850
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.01, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Carlyle and SK Capital complete acquisition of bluebird bio; stock delisted, new CEO David Meek
--------------------------------------------------------------------------------

- Acquisition closed June 2, 2025; shareholders could elect $3.00 + one CVR per share, or $5.00 all-cash per share.
- Approximately 59.8% of outstanding shares validly tendered before expiration; all conditions satisfied.
- David Meek appointed CEO; prior CEO Andrew Obenshain and other executives terminated, eligible for severance.
- Stock halted and delisted from Nasdaq; company will file Form 15 to terminate registration.
- Carlyle and SK Capital provide primary capital to support scaled access to gene therapies for sickle cell, β-thalassemia, and CALD.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1293971/000119312525132850/0001193125-25-132850-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1293971/000119312525132850/d39702d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-132850

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer